Ana Paula Picaro Michelli

Ana Paula Picaro Michelli

Auto-generated profile, based on publicly available information

Ana Paula Picaro Michelli

Univ Fed Sao Paulo, Thyroid Mol Sci Lab, Dept Biol Sci, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in European Journal of Breast Health
Verified
Journal Article
Closed access
Daniel Rodrigues de BastosDaniel Rodrigues de Bastos
Daniel Rodrigues de Bastos
MCMércia Patrícia Ferreira Conceição
Mércia Patrícia Ferreira Conceição
AMAna Paula Picaro Michelli
Ana Paula Picaro Michelli
JLJean Leite
Jean Leite
RSRafael A Silva
Rafael A Silva
Antonio Marcio Teodoro Cordeiro SilvaAntonio Marcio Teodoro Cordeiro Silva
Antonio Marcio Teodoro Cordeiro Silva
Objective: Breast cancer (BC) is the main cause of cancer-related deaths in women across the world. It can be classified into different subtypes, including triple-negative (TN), which is characterized by the absence of hormone receptors for estrogen and progesterone and the lack of the human epidermal growth factor receptor 2. These tumors have high heterogeneity, acquire therapeutic resistance, and have no established target-driven treatment yet. The identification of differentially expressed genes in TN breast tumors and the in silico validation of their prognostic role in these tumors. Materials and Methods: We employed a microarray dataset and, by using the GEO2R tool, we identified a list of differentially expressed genes. The in silico validation was conducted using several online platforms including the KM Plotter, cBioPortal, bc-GenExMiner, Prognoscan, and Roc Plotter. Results: We observed that FZD9 was among the top differentially expressed genes in a cohort of patients with different TNBC subtypes. The FZD9 expression was significantly different in TN breast tumors than in non-TN (nTN) breast tumors (p<0.0001), and the basal TN subtype showed the highest levels (p<0.0001). In addition, the FZD9 levels were significantly inversely and positively proportional (p<0.0001) to estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 clinical parameters. The high levels of FZD9 were associated with worse overall survival (p=0.007), relapse-free survival (p=5.8e-05), and worse survival in patients who received chemotherapy (p=3.2e-05; 0.007). Conclusion: Our cumulative results demonstrated that FZD9 plays an important role in TNBC and may be a potential prognostic biomarker. Nevertheless, further in vitro and in vivo assays are necessary to confirm our findings and to strengthen the evidences about the mechanisms by which FZD9 functions in these tumors.